Navigation Links
Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD334 for Autoimmune Diseases
Date:4/5/2013

SAN DIEGO, April 5, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the initiation of dosing in a Phase 1 clinical trial of APD334, a novel oral drug candidate that targets the sphingosine 1-phosphate subtype 1 (S1P1) receptor for the potential treatment of autoimmune diseases.

This randomized, double-blind and placebo-controlled Phase 1 trial will evaluate the safety, tolerability and pharmacokinetics of single-ascending doses of APD334 in up to 64 healthy adult volunteers.

"We are pleased to expand our clinical-stage pipeline by initiating a Phase 1 trial of APD334, and look forward to advancing this novel compound through our validated development platform," said William R. Shanahan , M.D., Arena's Senior Vice President and Chief Medical Officer. "APD334's selectivity for the S1P1 receptor has the potential to improve upon the adverse event profile of currently available treatments for a spectrum of autoimmune diseases."

About Autoimmune DiseasesAutoimmune diseases are characterized by an inappropriate immune response against substances and tissues that are normally present in the body. In an autoimmune reaction, a person's antibodies and immune cells target healthy tissues, triggering an inflammatory response. Reducing the immune and/or inflammatory response is an important goal in the treatment of autoimmune disease.

About APD334APD334 is an orally available drug candidate discovered by Arena that targets the S1P1 receptor for the potential treatment of a number of conditions related to autoimmune diseases, including multiple sclerosis, psoriasis and rheumatoid arthritis. S1P1 receptors have been demonstrated to be involved in the modulation of several biological responses, including lymphocyte trafficking from lym
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Arena Pharmaceuticals Provides Corporate Update and Reviews Fourth Quarter and Full Year 2012 Financial Results
2. Arena Pharmaceuticals to Present at the Cowen and Company 33rd Annual Health Care Conference
3. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Monday, March 4
4. Proposed Regulatory Uniformity to Boost Venture Capital Investments in Healthcare Arena, Says Frost & Sullivan
5. Arena Pharmaceuticals to Present at the Oppenheimer 23rd Annual Healthcare Conference
6. Arena Pharmaceuticals and Ildong Pharmaceutical Enter Into Co-Development and License Agreement for Temanogrel, a Novel Agent for Thrombotic Diseases
7. Arena Pharmaceuticals to Webcast Live Presentation at the Piper Jaffray 24th Annual Healthcare Conference
8. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2012 Financial Results
10. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Tuesday, November 6
11. Arena Pharmaceuticals to Present at the UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014   Decision Resources Group finds that ... chronic kidney disease non-dialysis (CKD-ND) patients are not ... In addition, one-year persistency is similar between Amgen,s ... key findings from the report entitled ... Stimulating Agents in Late Stage Chronic Kidney Disease ...
(Date:9/30/2014)... Ind. , Sept. 30, 2014  The orthopedic specialists ... the nation,s No. 6 orthopedic group by US News ... Active Adults," a series of free, public seminars to ... all over the world come to see the knee ... procedures are now available at Munster Specialty Surgery Center. ...
(Date:9/30/2014)... In 2011, approximately 5.1 million people in ... pain relievers (e.g. opioids). 1 Clinical treatments for ... the use of buprenorphine, buprenorphine/naloxone, naltrexone or methadone. The ... developing and improving care management programs, according to ... Therapeutics LLC (Prime). Cost trends ...
Breaking Medicine Technology:Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 2Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 3"Knee Pain Solutions for Active Adults" Complimentary Seminars Open to the Public 2Studies show cost and use of opioid dependence treatment are increasing, spurring the need for care management programs 2Studies show cost and use of opioid dependence treatment are increasing, spurring the need for care management programs 3
... , LITTLE FALLS, N.J., Dec. 2 ... the results for its first quarter ended October 31, 2009 on ... to discuss the results at 11:00 AM ET. Participating in ... President and CEO; Seth R. Segel, Executive Vice President; Craig A. ...
... , , CENTENNIAL, Colo., Dec. 2 ... bone and soft tissue allografts for use in surgical procedures ... substitutes, today announced its sponsorship of a truly iconic symbol ... Life float in the January 1, 2010 Tournament of Roses ...
Cached Medicine Technology:Cantel Medical Corp. to Hold Conference Call to Discuss Results for its First Quarter Ended October 31, 2009 2AlloSource Sponsors Heroic Quadruple Amputee as Rider Aboard 2010 Donate Life Rose Parade Float 2AlloSource Sponsors Heroic Quadruple Amputee as Rider Aboard 2010 Donate Life Rose Parade Float 3
(Date:9/30/2014)... With the flu season upon ... day, it’s a perfect time to announce Jan-Pro’s ... is an electro-static disinfectant delivery system that dries ... missed with spray-on disinfectant applicators. , The EnviroShield ... electrostatic negative charge to the disinfecting solution. ...
(Date:9/30/2014)... A group of Americans is headed to a remote ... unchecked, could create a catastrophic, global pandemic. No, it’s not ... Rogers, the Executive Director the Eugene Bell Foundation and his ... most think mankind conquered long ago: tuberculosis. , “Tuberculosis, mostly ... the comeback in several countries - what’s especially disconcerting is ...
(Date:9/30/2014)... September 30, 2014 Two revolutionary procedures now ... treatment of gum disease a far less painful and ... , “If you’ve ever felt electric shock waves surge through ... a cold beverage, it’s possible you already know the impact ... is a general dentist in West Palm Beach, and a ...
(Date:9/30/2014)... 30, 2014 (HealthDay News) -- Medicare should cover low-dose ... risk for the disease, a coalition of more than ... which includes the Lung Cancer Alliance, the Society of ... Cancer Society and the American Society of Clinical Oncology, ... the U.S. Centers for Medicare & Medicaid Services (CMS). ...
(Date:9/30/2014)... has made progress in reducing the stigma associated with ... post-traumatic stress disorder, but more improvement is still needed, ... efforts of both the Defense Department and the Veterans ... members still do not seek needed care for ... effort to promote treatment as a way to reduce ...
Breaking Medicine News(10 mins):Health News:Columbus Janitorial Company Announces New Disinfecting System for your workplace 2Health News:US Delegation Heads to North Korea to Combat Tuberculosis Epidemic 2Health News:Florida Dentist Battles Gum Disease With Latest Techniques 2Health News:Florida Dentist Battles Gum Disease With Latest Techniques 3Health News:Groups Call for Medicare Coverage of Lung Cancer Screening 2Health News:US military making progress reducing stigma tied to seeking help for mental illness 2Health News:US military making progress reducing stigma tied to seeking help for mental illness 3
... Dec. 12 (HealthDay News) -- Severe side effects may be ... taking drugs that can help prevent a tumor,s return, a ... gap between what these breast cancer patients tell their doctors ... to the study authors from Northwestern University in Chicago. ...
... Henry Ford Hospital have found that one-quarter of severe asthma ... medication as prescribed. Moreover, an asthma attack was only ... their prescribed dose, according to the study. Patients often ... of symptoms. Henry Ford researchers say this is the ...
... myeloma are both malignant diseases that arise from lymphocytes, ... nodes and the bone marrow. Although considerable progress has ... remain a significant challenge for patients and their hematologists. ... lymphoma and myeloma will be presented today at the ...
... is available in German . Seabirds often ... as fleas and ticks, take advantage of this ideal habitat ... can transmit blood parasites like avian malaria to the birds. ... and a team of international colleagues have investigated whether this ...
... How should insights about the brain affect the course of ... the issuing of a sentence? This was ... at the Society for Neuroscience,s "Neuroscience 2011." Titled "The Brain ... how advances in neuroscience are both challenging and assisting the ...
... HealthDay Reporter , SUNDAY, Dec. 11 (HealthDay News) -- ... with severe sickle cell anemia can also help young children ... sickle cell anemia younger than 4 years old who took ... hospital admissions, illnesses with fever and need for transfusions, the ...
Cached Medicine News:Health News:Side Effects Cause Many Older Women to Drop Breast Cancer Drugs 2Health News:Improved medication use could reduce severe asthma attacks 2Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 2Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 3Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 4Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 5Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 6Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 7Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 8Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 9Health News:Only few seabird species contract avian malaria 2Health News:Only few seabird species contract avian malaria 3Health News:The brain on trial 2Health News:Adult Sickle Cell Drug May Benefit Kids, Too 2Health News:Adult Sickle Cell Drug May Benefit Kids, Too 3
The fat loss formula's key ingredient of 2.0% aminophylline works by penetrating deep into the skin where it causes the body fat cells to shrink, resulting in up to 2 inches of body fat loss....
... VelaSmooth is the first ... device with the revolutionary elos ... Radio Frequency and Infrared Light ... with suction to reduce the ...
... was designed with the physician, staff ... you the best economy exam room ... does not skimp on patient comfort. ... can easily position patients so that ...
The Salt A-Peel™ microdermabrasion combines, positive air pressure, pure salt, ultrasound and the application of rich anti oxidant products to deliver a remarkable 'The Salt A-Peel' anti ageing...
Medicine Products: